However, a phase II trial studying the efficacy in adult CBF-AML patients of the FLAG induction regimen as frontline therapy in combination with GO 3 mg/mq at induction day 1 and post-remission course 1 and 2 day 1 (FLAG-GO), showed that FLAG-GO induced a higher remission rate (95.0%) and it was associated with a 3-year OS and RFS of 78.0% and 85.0%, respectively [92]. Here, CEBPZ is linked to acute myeloid leukemia.